Cancer cell-derived exosome based dual-targeted drug delivery system for non-small cell lung cancer therapy.
Colloids Surf B Biointerfaces
; 244: 114141, 2024 Dec.
Article
em En
| MEDLINE
| ID: mdl-39216444
ABSTRACT
Lung cancer is among most prevalent cancers in the world, in which non-small cell lung cancer (NSCLC) accounts for more than 85â¯% of all subtypes of lung cancers. NSCLC is often diagnosed at an advanced stage with a high mortality rate. Despite the demonstrated efficacy of chemotherapy in the treatment of NSCLC, the main drawback of current therapy is the lack of an effective drug-targeted delivery system, which may result in undesirable side effects during the clinical treatment. In this study, we construct a "dual-targeting" anti-cancer drug delivery platform by combining superparamagnetic iron oxide nanoparticles (SPIONs) with exosomes derived from NSCLC cells. We successfully promoted the targeted delivery of anti-drug doxorubicin (DOX) at the cellular levels by combining the homing targeted ability of exosomes with the magnetic targeted ability of SPIONs. Moreover, non-small cell lung cancer cell (NCI-h1299) tumor models were established. It was found that exosome-SPIONs (Exo-SPIONs) loaded with DOX exhibited optimal tumor tissue delivery and tumor suppression in the presence of an external magnetic field, and reduced the toxicity of the DOX to normal tissues. The constructed "dual-targeting" anti-cancer drug delivery platform holds promise for targeted chemotherapy for NSCLC.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doxorrubicina
/
Sistemas de Liberação de Medicamentos
/
Carcinoma Pulmonar de Células não Pequenas
/
Exossomos
/
Neoplasias Pulmonares
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article